Robert Michael Dudley - Net Worth and Insider Trading
Robert Michael Dudley Net Worth
The estimated net worth of Robert Michael Dudley is at least $4,463 dollars as of 2024-06-23. Robert Michael Dudley is the CEO of TransCode Therapeutics Inc and owns about 4,507 shares of TransCode Therapeutics Inc (RNAZ) stock worth over $4,463. Details can be seen in Robert Michael Dudley's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Robert Michael Dudley has not made any transactions after 2023-09-28 and currently still holds the listed stock(s).
Transaction Summary of Robert Michael Dudley
Robert Michael Dudley Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Robert Michael Dudley owns 1 companies in total, including TransCode Therapeutics Inc (RNAZ) .
Click here to see the complete history of Robert Michael Dudley’s form 4 insider trades.
Insider Ownership Summary of Robert Michael Dudley
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RNAZ | TransCode Therapeutics Inc | 2023-09-28 | director & 10 percent owner & Chief Executive Officer |
Robert Michael Dudley Latest Holdings Summary
Robert Michael Dudley currently owns a total of 1 stock. Robert Michael Dudley owns 4,507 shares of TransCode Therapeutics Inc (RNAZ) as of September 28, 2023, with a value of $4,463.
Latest Holdings of Robert Michael Dudley
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RNAZ | TransCode Therapeutics Inc | 2023-09-28 | 4,507 | 0.99 | 4,463 |
Holding Weightings of Robert Michael Dudley
Robert Michael Dudley Form 4 Trading Tracker
According to the SEC Form 4 filings, Robert Michael Dudley has made a total of 6 transactions in TransCode Therapeutics Inc (RNAZ) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in TransCode Therapeutics Inc is the acquisition of 2,450 shares on September 28, 2023, which cost Robert Michael Dudley around $49,980.
Insider Trading History of Robert Michael Dudley
- 1
Robert Michael Dudley Trading Performance
GuruFocus tracks the stock performance after each of Robert Michael Dudley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert Michael Dudley is -60.98%. GuruFocus also compares Robert Michael Dudley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert Michael Dudley within 3 months outperforms 0 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Robert Michael Dudley's insider trading performs compared to the benchmark.
Performance of Robert Michael Dudley
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -21.19 | | | | | |
| Relative Return to S&P 500(%) | -19.14 | | | | | |
Robert Michael Dudley Ownership Network
Robert Michael Dudley Owned Company Details
What does TransCode Therapeutics Inc do?
Who are the key executives at TransCode Therapeutics Inc?
Robert Michael Dudley is the director & 10 percent owner & Chief Executive Officer of TransCode Therapeutics Inc. Other key executives at TransCode Therapeutics Inc include director & VP & Chief Financial Officer Thomas A Fitzgerald , 10 percent owner Anna Moore , and 10 percent owner Zdravka Medarova .
TransCode Therapeutics Inc (RNAZ) Insider Trades Summary
Over the past 18 months, Robert Michael Dudley made 4 insider transaction in TransCode Therapeutics Inc (RNAZ) with a net purchase of 154,607. Other recent insider transactions involving TransCode Therapeutics Inc (RNAZ) include a net purchase of 49,350 shares made by Thomas A Fitzgerald ,
In summary, during the past 3 months, insiders sold 0 shares of TransCode Therapeutics Inc (RNAZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TransCode Therapeutics Inc (RNAZ) were sold and 5,099 shares were bought by its insiders, resulting in a net purchase of 5,099 shares.
TransCode Therapeutics Inc (RNAZ)'s detailed insider trading history can be found in Insider Trading Tracker table.
TransCode Therapeutics Inc Insider Transactions
Robert Michael Dudley Mailing Address
Above is the net worth, insider trading, and ownership report for Robert Michael Dudley. You might contact Robert Michael Dudley via mailing address: C/o Transcode Therapeutics, 6 Liberty Square #2382, Boston Ma 02109.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
